Skip to main content
. Author manuscript; available in PMC: 2020 Apr 14.
Published in final edited form as: J Oncol Pharm Pract. 2017 Mar 26;24(4):290–298. doi: 10.1177/1078155217702213

Figure 1.

Figure 1.

The percentage of patients that developed grade >3 cardiotoxicity in the presence or absence of baseline cardiac comorbidities in each renal function group.